Clinical trial
DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome…
NCT00496652 · Danish Head and Neck Cancer Group, Other · Completed
Key facts
| NCT number | NCT00496652 |
|---|---|
| Title | DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC |
| Official title | DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Danish Head and Neck Cancer Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer of the Head and Neck |
| Intervention type | Drug, Radiation |
| Interventions | Radiotherapy, Zalutumumab |
| Enrollment | 619 |
| Start date | Nov 1, 2007 |
| Primary completion | Jul 1, 2012 |
| Completion | Nov 1, 2016 |
| First posted | Jul 4, 2007 |
| Last update posted | Nov 25, 2016 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: